文献速递甲状腺核医学肿瘤 PET/CT

18F-氟胆碱PET/CT探测异常甲状旁腺:适应证、实践、判读与诊断效能

18F-Fluorocholine-Positron Emission Tomography/Computerized Tomography (FCH PET/CT) Imaging for Detecting Abnormal Parathyroid Glands: Indication, Practice, Interpretation and Diagnostic Performance.
PubMed 文献 · Semin Nucl Med · 2024-09-20

本文总结18F-氟胆碱PET/CT(FCH PET/CT)在甲状旁腺功能亢进症(HPT)患者中的文献证据,涵盖适应证、安全性、操作实践与判读要点。FCH PET/CT探测异常甲状旁腺的灵敏度为97%(范围96%-98%),优于其他放射性药物、超声或4D-CeCT。作者基于12年真实世界经验认为,FCH PET/CT可作为所有类型HPT且适合手术患者的一线核医学影像技术。

要点

  • FCH PET/CT探测异常甲状旁腺灵敏度97%(范围96%-98%),诊断效能优于其他放射性药物、超声或4D-CeCT。
  • 术前定位可优化甲状旁腺切除术式,选择适合微创甲状旁腺切除术的患者。
  • 作者12年真实世界经验支持FCH PET/CT作为适合手术的所有类型HPT患者的一线核医学影像技术。

核心结论

  • 作者基于12年真实世界经验认为,FCH PET/CT可作为所有类型HPT且适合手术患者的一线核医学影像技术。
  • FCH PET/CT探测异常甲状旁腺的灵敏度为97%(范围96%-98%),诊断效能优于其他放射性药物、超声或4D-CeCT。

研究设计与样本

  • 本文为综述,汇总FCH PET/CT在HPT患者中的文献证据,并结合作者12年真实世界经验。
  • 文献涵盖异质性患者系列,包括原发性HPT与肾性HPT,后者报道系列较少。

主要发现

  • FCH PET/CT探测异常甲状旁腺的灵敏度为97%(范围96%-98%)。
  • FCH PET/CT诊断效能优于其他放射性药物、超声或4D-CeCT。
  • 术前定位研究使甲状旁腺切除术失败率显著降低,尤其因未疑及的多腺体或异位病变所致者。
  • 微创甲状旁腺切除术可缩短手术时间、切口长度并降低手术风险。

关键数值与推荐

  • FCH PET/CT探测异常甲状旁腺灵敏度97%,范围96%-98%。

临床怎么用

  • 作者认为,FCH PET/CT可作为所有类型HPT且适合手术患者的一线核医学影像技术。
  • 术前影像可优化甲状旁腺切除术式,选择适合微创甲状旁腺切除术的患者。

局限性

  • FCH PET/CT在肾性HPT中的效用报道系列较少。
  • 文献数据来自异质性患者系列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In patients with confirmed hyperparathyroidism (HPT) scheduled for surgical treatment, the preoperatory imaging permits to optimize the operatory protocol of parathyroidectomy (PTX), in particular by selecting those patients who can benefit from minimally invasive PTX (MIPTX). The MIPTX has the merit to shorten the operative time, incision length, and to reduce the operatory risks. With preoperative localization studies, the rate of PTX failure, in particular due to nonsuspected multiglandular or ectopic disease, has been profoundly decreased. The first cases of incidental localization of abnormal parathyroid glands (PTs) on FCH PET/CTs performed for another indication were reported more than one decade ago. Since then, significant amount of data from heterogeneous series of patients consistently confirmed better diagnostic performances of FCH PET/CT (sensitivity for detection of abnormal PT 97%, range 96%-98%) in comparison with other radiopharmaceuticals, ultrasonography or 4D-CeCT in localizing hyperfunctioning parathyroid glands (HFPTGs) in case of primary HPT. Utility of FCH PET/CT in case of renal HPT has been reported in fewer series. The article discusses and summarizes the bibliographic evidence on documented indications of FCH PET/CT in patients with HPT, its safety profile, the practice of FCH PET/CT and interpretation of FCH PET/CT findings, including potential interpretation pitfalls and tips to avoid them. Our real-world experience over 12 years reinforces published evidence supporting the use of FCH PET/CT as the first-line radionuclide imaging technique in patients with all types of HPT in whom surgery is an option.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Noskovicova L, Balogova S, Aveline C, et al. 18F-Fluorocholine-Positron Emission Tomography/Computerized Tomography (FCH PET/CT) Imaging for Detecting Abnormal Parathyroid Glands: Indication, Practice, Interpretation and Diagnostic Performance. Semin Nucl Med. 2024. PMID: 39306520. doi:10.1053/j.semnuclmed.2024.08.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。